Sbc Medical Group Holdings Incorporated · NASDAQ:SBC
Sbc Medical — Q2 2025 Earnings Presentation
30 slides from Sbc Medical's earnings presentation, August 2025
Slide 1: Investor Presentation 2Q2025
2Q2025 Investor Presentation August 2025
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain
Slide 3: Table of Contents
Table of Contents Ⅰ. Franchise Clinics Performance Highlights P4 Ⅱ. Financial Results for 2Q25 P8 Ⅲ. Business Strategies by Segment P10 Ⅳ. Use of Assets, Capital Strategy P16 Appendix P20 3
Slide 4: Ⅰ. Franchise Clinics Performance Highlights
Ⅰ. Franchise Clinics Performance Highlights 4
Slide 5: Group Structure and Business Model
Group Structure and Business Model • SBC provides comprehensive consulting and management services to the medical corporations and their clinics through a franchise model US Franchise Clinics SBC Medical Group Holdings, Inc. Total Revenue: US$1.1bn in FY2024 Total Revenue: US$205mm in FY2024 Aesthet
Slide 6: 1H25 Franchise Clinics Performance Highlights
1H25 Franchise Clinics Performance Highlights • With the addition of JUN CLINIC, the number of franchise locations has expanded to 259, and the annual number of customer visits continues to grow steadily Franchise Clinics Key Figures Number of Franchise Locations¹ Repeat Rate² ³ ⁴ Total Revenue⁵ ⁶ ⁸
Slide 7: Trends in Number of Locations and Customers
Trends in Number of Locations and Customers • Our network of clinics and our customer base are continually expanding, solidifying our position as a market leader with an international presence Number of Locations¹ Number of Customers² ³ – Historical Trend (until July 2025) – Historical Trend (until
Slide 8: Ⅱ. Financial Results for 2Q25
Ⅱ. Financial Results for 2Q25 8
Slide 9: Income Statement (Consolidated)
Income Statement (Consolidated) • The foundation for future growth has been solidified, although revenues declined due to business restructuring (withdrawal from the staffing business and deconsolidation of certain affiliates) and revisions to franchise fees 2Q25 2Q24 1H25 1H24 1 Total revenues % Yo
Slide 10: Ⅲ. Business Strategies by Segment
Ⅲ. Business Strategies by Segment 10
Slide 11: JUN CLINIC's Participation
Aesthetic Medicine Business Medical Business Overseas Business JUN CLINIC's Participation • Through this strategic acquisition, SBC expects to expand its beauty clinic business domain and strengthen its aesthetic dermatology domain Acquisition Overview Strategic Background • MB Career Lounge, Inc. (
Slide 12: Strategic Initiatives in Aesthetic Dermatology
Aesthetic Medicine Business Medical Business Overseas Business Strategic Initiatives in Aesthetic Dermatology • To accurately capture diversifying customer base, we are promoting a multi-brand strategy • Accelerating our shift from general surgery to efficient, specialized dermatology in response to
Slide 13: Medical Tourism Strategy
Aesthetic Medicine Business Medical Business Overseas Business Medical Tourism Strategy • The number of overseas customers seeking Japan's high-quality and safe medical services continues to grow, particularly from China • Strengthening foreign language support and information dissemination in China
Slide 14: Strategic Initiatives in The Medical Business
Aesthetic Medicine Business Medical Business Overseas Business Strategic Initiatives in The Medical Business • Selectively expanding medical business in areas such as orthopedics, infertility treatment, and Alopecia treatment (AGA) from the perspectives of profitability and growth potential • Levera
Slide 15: Strategic Initiatives in Overseas Business
Aesthetic Medicine Business Medical Business Overseas Business Strategic Initiatives in Overseas Business • Accumulate knowledge and experience in business operations in the United States and begin laying the groundwork for future expansion of U.S. operations • Strengthening collaboration with Aesth
Slide 16: Ⅳ. Use of Assets, Capital Strategy
Ⅳ. Use of Assets, Capital Strategy 16
Slide 17: Robust Balance Sheet Positioned for Growth
Robust Balance Sheet Positioned for Growth • A solid financial foundation with ample cash reserves and borrowing capacity, primarily intended for future growth investments Key Balance Sheet Figures (as of Jun 30, 2025) Selected items from Balance Sheet Jun 30, Dec 31, (MM US$) 2025 Change 2024 Total
Slide 18: Current Challenges of SBC's Shares
Current Challenges of SBC’s Shares • The low liquidity of our shares makes it difficult for many institutional investors to trade • ① Improving the supply-demand balance of shares and ② considering and implementing additional liquidity provisions in parallel Current Challenge on SBC’s Shares Ideal P
Slide 19: Share Buy Back Result, Membership in Russell3000
Share Buy Back Result, Membership in Russell3000 • Share buybacks were implemented beginning May 2025. This had a certain positive impact on both stock price and liquidity. The company will continue to monitor market performance and implement various measures accordingly • Added to Russell 3000 on J
Slide 20: Appendix
Appendix SBC Medical Group Holdings, Inc. 20
Slide 21: 1H25 Financial Performance Highlights
1H25 Financial Performance Highlights • Revenue and EBITDA decreased due to last year's business restructuring and the fee revisions in April 2025 • Net income decreased as a result of higher effective tax rates due to differences between Japanese and US accounting standards SBC Medical Group Holdin
Slide 22: Income Statement (Consolidated)
Income Statement (Consolidated) Income Statement Operating Expenses 2Q25 % YoY 2Q24 1H25 % YoY 1H24 2Q25 % YoY 2Q24 1H25 % YoY 1H24 (MM US$) (MM US$) Total revenues 43 (18)% 53 91 (16)% 108 Total operating expenses 15 +27% 12 29 +7% 27 Franchising Revenue 10 (32)% 15 26 (13)% 30 Salaries and welfare
Slide 23: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) Jun 30, Dec 31, Jun 30, Dec 31, (MM US$) 2025 Change 2024 (MM US$) 2025 Change 2024 Total assets 315 +49 266 Total liabilities 71 (0) 71 Total current assets 241 +57 184 Total current liabilities 61 (0) 61 Cash and cash equivalent 153 +28 125 Accounts payable 16 +2 14 No
Slide 24: Cash Flows (Consolidated)
Cash Flows (Consolidated) 1H25 1H24 (MM US$) % YoY Net cash provided by (used in) operating activities (6) n.m. 23 Net cash provided by (used in) investing activities 15 n.m. (9) Net cash provided by (used in)financing activities 7 n.m. (0) Effect of exchange rate changes 12 n.m. (13) Net change in
Slide 25: 2Q25 Revenue Trend (vs 2Q24)
2Q25 Revenue Trend（vs 2Q24） • Revenue¹ decreased year-over-year due to business restructuring and revisions of franchise fee structure (MM US$) （4.9） (5.3) (0.6) +1.4 +2.2 +3.4 +0.5 (1.1) (7.4) (4.0) 53.1 47.2 43.4 42.3 13,094 2Q24 Termination of Deconsolidation 2Q24 Revision of Franchising Procurem
Slide 26: 2Q25 EBITDA Trend (vs 2Q24)
2Q25 EBITDA¹ Trend (vs 2Q24) • Even after business restructuring, EBITDA declined due to the impact of fee structure revisions and increased cost of sales and other operating expenses (MM US$) （12.5） (0.8) +3.5 +1.1 (7.4) (5.1) (1.3) (2.9) (0.4) 28.1 27.3 15.2 14.8 2Q24 Impact of Structural 2Q24 Rev
Slide 27: 1H25 Revenue Trend (vs 1H24)
1H25 Revenue Trend（vs 1H24） • Revenue¹ increased year-over-year, excluding the impact of business restructuring (MM US$) （5.1） (10.8) +1.2 +3.4 +5.4 (3.5) (0.0) (7.4) (5.4) (2.2) 107.9 93.6 90.7 88.5 13,094 1H24 Termination of Deconsolidation 1H24 Revision of Franchising Procurement Management Renta
Slide 28: 1H25 EBITDA Trend (vs 1H24)
1H25 EBITDA¹ Trend (vs 1H24) • Even after business restructuring, higher cost of goods sold and other operating expenses led to a decline in EBITDA (MM US$) （11.9） (2.7) +4.5 +1.2 (7.4) (5.9) (2.0) (1.3) (1.0) 53.6 28.1 50.9 27.3 40.0 15.2 14.8 39.0 1H24 Impact of Structural 1H24 Revision of Others
Slide 29: Non-GAAP Financial Measures
Non-GAAP Financial Measures • This presentation may reference certain non-GAAP financial measures. Reconciliations of such measures to the most directly comparable GAAP measures are shown below Reconciliation Table on Non-GAAP Financials （MM US$） 2Q25 2Q24 1H25 1H24 (A) Total Revenues 43 53 91 108 (
Slide 30: Thank you
Thank you SBC Medical Group Holdings Incorporated / ir@sbc-holdings.com ICR, LLC / US Investor Contact / +1 (646) 277 1200 /William.Zima@icrinc.com
SBC Medical Group Holdings — Q2 2025 Earnings Presentation on 6ix